Drug-gene interaction the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 212-218

  Schelleman, Hedi ^a,b   Klungel, Olaf H ^b   Van Duijn, Cornelia M ^a   Witteman, Jacqueline C M ^a   Hofman, Albert ^a   De Boer, Anthonius ^b   Stricker, Bruno H Ch ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Angiotensin converting enzyme gene; Polymorphism

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NETHERLANDS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; GENOTYPE; HUMANS; HYPERTENSION; MALE; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33144459415     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G316     Document Type: Article

References (22)

1. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
2. Schunkert H. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease. J Mol Med 1997;75:867-75.
3. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995;13:1602-9.
4. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996;14:259-62.
5. Nakano Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G, Kambe M. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997;10:1064-8.
6. Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997;10:951-5.
7. O'Toole L, Stewart M, Padfield P, Channer K. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998;32:988-94.
8. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998;11:174-83.
9. Stavroulakis GA, Makris TK, Hatzizacharias AN, Anastasiadis G, Triposkoadis P, Kyriakidis MK. Predicting response to chronic antihypertensive treatment with fisinopril: the role of the angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000;14:427-32.
10. Li X, Du Y, Huang X. Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003;8:25-30.
11. Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment. The Genetics of Hypertension-Associated Treatment (Gen-HAT) Study. Circulation 2005;111:3374-83.
12. Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001;19:1783-7.
13. Blumenfeld JD, Sealey JE, Mann SJ, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin- aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-9.
14. Weisser B, Ripka O. Long-term diuretic therapy: effects of dose reduction on antihypertensive efficacy and counterregulatory systems. J Cardiovasc Pharmacol 1992;19:361-6.
15. Muller FB, Bolli P, Erne P, Kiowski W, Buhler FR. Use of calcium antagonists as monotherapy in the management of hypertension. Am J Med 1984;77:11-5.
16. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-22.
17. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706-11.
18. Guidelines for ATC classification and DDD assignment. 3rd ed. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2000.
19. Yu XL, Jin XR, Wang DX. Effects of cigarette smoking on the function of metabolizing arachidonic acid and angiotensin I in the isolated perfused rat lungs. J Tongji Med Univ 1992;12:201-4.
20. Schut AF, Sayed-Tabatabaei FA, Witteman JC, et al. Smoking-dependent effects of the angiotensin-converting enzyme gene insertion/deletion polymorphism on blood pressure. J Hypertens 2004;22:313-9.
21. Sciarrone MT, Stella P, Barlassina C, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003;41:398-403.
22. Zhu X, Bouzekri N, Southam L, et al. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet 2001;68:1139-48.